Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Status:
Completed
Trial end date:
2017-03-22
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies how well buparlisib works in treating patients with
non-Hodgkin lymphoma that has returned after a period of improvement or has not responded to
previous treatment. Buparlisib may stop the growth of cancer cells by blocking some of the
enzymes needed for cell growth.